Sponsored by **Carcinoma of the Cervix** ICCR **Histopathology Reporting Guide** Family/Last name Date of birth DD – MM – YYYY Given name(s) Patient identifiers Date of request Accession/Laboratory number DD – MM – YYYY Elements in **black text** are CORE. Elements in grey text are NON-CORE. SCOPE OF THIS DATASET indicates multi-select values CLINICAL INFORMATION (select all that apply) SPECIMEN DIMENSIONS Information not provided Cannot be assessed Previous procedure performed Number of tissue pieces^b Loop excision^a/Cone biopsy Trachelectomy (simple or radical) **Tissue piece dimensions**^b (*Record for each piece*) Previous therapy mm x mm x mm Chemotherapy Radiotherapy Other, *specify* mm | x mm x mm mm x mm x mm **SPECIMEN(S) SUBMITTED** (select all that apply) Cervix^c O Not specified Diameter of Loop excision^a/Cone biopsy mm mm ectocervix Trachelectomy O Radical ○ Type not specified ◯ Simple Length of specimen mm Hysterectomy Radical Type not specified ○ Simple Vaginal cuff^d Fallopian tube

O Not applicable

Minimum length

Maximum length

Left parametrium

O Not applicable

mm

mm

○ Not applicable							
Lateral extent	mm						
							
Right parametrium							
O Not applicable							
Lateral extent	mm						
^b Applicable to loop/cone biopsies only. ^c Applicable to loop/cone biopsies and trachelectomy specimens only. ^d Applicable to trachelectomy and hysterectomy specimens.							
					MACROSCOPIC APPEARANCE OF TUMOUR(S)		
(select all that apply)							
No macroscopicall	y visible tumour						
	Lateral extent Right parametrium Not applicable Lateral extent Applicable to loop/cone bic Applicable to loop/cone bic Applicable to trachelectom MACROSCOPIC APPEA (select all that apply)	Lateral extent mm Right parametrium Not applicable Lateral extent b Applicable to loop/cone biopsies only. c Applicable to loop/cone biopsies and trachelect d Applicable to trachelectomy and hysterectomy					

C Laterality not specified

○ Laterality not specified

C Laterality not specified

ically visible tumour Other node group, specify Exophytic/polypoid Flat Ulcerated Other, specify Circumferential/barrel shaped cervix Other, specify

^a Loop excision includes loop electrosurgical excision procedure (LEEP and large loop excision of the transformation zone (LLETZ)).

Left

Left

Left Vaginal cuff

Parametrium

Pelvic exenteration

Ovary

Lym

Right

Right

🗌 Right

Use of this dataset is only permitted subject to the details described at: Disclaimer - International Collaboration on Cancer Reporting (iccr-cancer.org) Version 5.0 Published October 2023 ISBN: 978-1-922324-43-6 Page 1 of 5

TUMOUR SITE (select all that apply)	HISTOLOGICAL TUMOUR TYPE
 No macroscopically visible tumour Ectocervix Anterior 	(Value list based on the World Health Organization Classification of Female Genital Tumours (2020)) Squamous cell carcinoma, HPV-associated
Posterior	 Squamous cell carcinoma, HPV-independent Squamous cell carcinoma NOS
Left lateral	 Adenocarcinoma, HPV-associated
Right lateral	 Adenocarcinoma, HPV-independent, gastric type
Circumference of cervix	 Adenocarcinoma, HPV-independent, clear cell type
Endocervix	 Adenocarcinoma, HPV-independent, mesonephric type
	\bigcirc Carcinosarcoma NOS
Posterior	 Adenosquamous carcinoma
Left lateral	Adenoid basal carcinoma
Right lateral Circumference of cervix	$\stackrel{\smile}{\bigcirc}$ Carcinoma of the uterine cervix, unclassifiable
	Neuroendocrine tumour NOS
	Small cell neuroendocrine carcinoma
Lower uterine segment	C Large cell neuroendocrine carcinoma
Corpus	Carcinoma admixed with neuroendocrine carcinoma
Parametrium	(specify percentage of each component)
Left	
Right	Other, <i>specify</i>
\bigcirc Laterality not specified	V Guici, specify
Other, <i>specify</i>	
•	
	HISTOLOGICAL TUMOUR GRADE (Applicable to some HPV-associated adenocarcinomas)
	◯ G1: Well differentiated
	G2: Moderately differentiated
TUMOUR DIMENSIONS	G3: Poorly differentiated
(If separate tumour foci, specify the dimensions for each)	Cannot be assessed, <i>specify</i>
Cannot be assessed	
Maximum horizontal	
tumour dimension mm at least ^e	
	LYMPHOVASCULAR INVASION
Depth of invasion mm at least ^e	
	O Not identified
OR 🕥 Not assessable	O Present
If we have a second black was and	
If not assessable record	EXTENT OF INVASION
Thickness mm	O Not applicable
	Fallopian tube
^e It is advisable to include 'at least' for the tumour measurements in loop or cone excisions when tumour is present at a resection margin(s). If not	Not applicable
applicable, delete 'at least'.	 ○ Not upplicable ○ Not involved
	Left Right
DEEPEST LOCATION OF TUMOUR WITHIN CERVICAL	
STROPIA	Ovary
Cannot be assessed	O Not applicable
O Superficial third	O Not involved
O Middle third	Involved
O Deepest third	Left Right
	Down w studium
	Parametrium
BLOCK IDENTIFICATION KEY	Not applicable Not involve d
(List overleaf or separately with an indication of the nature and origin of all tissue blocks)	Not involved Involved
	Left Right

Use of this dataset is only permitted subject to the details described at: Disclaimer - International Collaboration on Cancer Reporting (iccr-cancer.org) Version 5.0 Published October 2023 ISBN: 978-1-922324-43-6 Page 2 of 5

EXTENT OF INVASION continued	Bladder
Vagina Not applicable Not involved Involved Upper two thirds Lower third	 Not applicable Not involved Involved, specify compartment Rectosigmoid Not applicable
Lower uterine segment Not applicable Not involved Involved 	 Not applicable Not involved Involved, specify compartment
Endometrium	Other organs or tissues
 Not applicable Not involved Involved 	 Not applicable Not involved Involved, specify
Myometrium Not applicable Not involved Involved 	PATTERN CLASSIFICATION FOR HPV-ASSOCIATED

MARGIN STATUS

Invasive tumour

HYSTERECTOMY/TRACHELECTOMY SPECIMEN

LOOP/CONE

Margin	Not involved	Involved	Distance of tumour from margin (mm)	Cannot be assessed	Margin	Not involved	Involved	Distance of tumour from margin (mm)	Cannot be assessed
Ectocervical/vaginal cuff					Ectocervical				
Endocervical ^f					Endocervical				
Radial/deep stromal					Radial/deep stromal				
Closest lateral		C Left			Unspecified ⁹				

Precursor lesions

		HS	SIL			A	IS			SM	ILE		
Margin	Not involved	Involved	Distance of lesion from margin	Cannot be assessed	Not involved	Involved	Distance of lesion from margin	Cannot be assessed	Not involved	Involved	Distance of lesion from margin	Cannot be assessed	Margin is not applicable to specimen
Ectocervical/vaginal cuff													
Endocervical													
Radial/deep stromal													
Unspecified ⁹													

HSIL: High grade squamous intraepithelial lesion

AIS: Adenocarcinoma in situ

SMILE: Stratified mucin-producing intraepithelial lesion

^f This is required only for trachelectomy specimens. Distance to endocervical margin is required for trachelectomy specimens as it is often used by surgeons to decide whether to undertake a followup hysterectomy or to remove another portion of the cervix if technically possible.

⁹ Use for loop/cone biopsies where it is not possible to say whether the margin is ectocervical or endocervical.

Use of this dataset is only permitted subject to the details described at: Disclaimer - International Collaboration on Cancer Reporting (iccr-cancer.org) Version 5.0 Published October 2023 ISBN: 978-1-922324-43-6 Page 3 of 5

LYMPH NODE STATUS

 \bigcirc Cannot be assessed

No nodes submitted or found

Lymph node type	Laterality	Number of lymph nodes ^h	Number of lymph nodes with isolated tumour cells ^{h,i}	Number of lymph nodes with micrometastasis ^{h,j}	Number of lymph nodes with macrometastasis ^{h,j}
Sentinel node(s)	Left				
	Right				
Regional node(s): pelvic	Left				
	Right				
Regional node(s): para-aortic	1				
Non-regional node(s): inguinal	Left				
	Right				

ⁱ Isolated tumour cells ($\leq 0.2 \text{ mm or } \leq 200 \text{ cells}$).

^j Micrometastasis (>0.2 mm and ≤2 mm); Macrometastasis (>2 mm).

COEXISTENT PATHOLOGY/PRECURSOR LESIONS ^k	ANCILLARY STUDIES
Squamous intraepithelial lesion (SIL)/ Cervical intraepithelial neoplasia (CIN)	 Not performed Performed (select all that apply)
 Not identified Present GRADE Low grade SIL (LSIL)/(CIN 1) High grade SIL (HSIL)/(CIN 2/3) 	HPV testing, record result(s)
HPV-associated adenocarcinoma in situ/High grade cervical glandular intraepithelial neoplasia (HG CGIN)	Immunohistochemistry, <i>specify test(s) and result(s)</i>
 Not identified Present 	
Stratified mucin-producing intraepithelial lesion (SMILE)	
 Not identified Present 	Other, specify test(s) and result(s)
Other possible precursor lesions	
 Not identified Present (select all that apply) Adenocarcinoma in situ of gastric type Lobular endocervical glandular hyperplasia Atypical lobular endocervical glandular hyperplasia Other, <i>specify</i> 	Representative blocks for ancillary studies, specify those blocks best representing tumour and/or normal tissue for further study
^k Core for loop/cone excisions/trachelectomies only; non-core for other specimens.	

Use of this dataset is only permitted subject to the details described at: Disclaimer - International Collaboration on Cancer Reporting (iccr-cancer.org) Version 5.0 Published October 2023 ISBN: 978-1-922324-43-6 Page 4 of 5

PROVISIONAL PATHOLOGICAL STAGING

FIGO (2018 edition)

- $\bigcirc I$ The carcinoma is strictly confined to the cervix (extension to the corpus should be disregarded)
 - IA Invasive carcinoma that can be diagnosed only by microscopy with maximum depth of invasion $\leq 5 \text{ mm}^{\text{m}}$
 - \bigcirc IA1 Measured stromal invasion \leq 3 mm in depth
 - \bigcirc IA2 Measured stromal invasion >3 mm and \leq 5 mm in depth
 - IB Invasive carcinoma with measured deepest invasion >5 mm (greater than stage IA), lesion limited to the cervix uteri with size measured by maximum tumour diameterⁿ
 - IB1 Invasive carcinoma >5 mm depth of stromal invasion and ≤ 2 cm in greatest dimension
 - () IB2 Invasive carcinoma >2 cm and ≤4 cm in greatest dimension
 - () IB3 Invasive carcinoma >4 cm in greatest dimension
- () II The carcinoma invades beyond the uterus, but has not extended onto the lower third of the vagina or to the pelvic wall
 - IIA Involvement limited to the upper two-thirds of the vagina without parametrial invasion
 - () IIA1 Invasive carcinoma ≤ 4 cm in greatest dimension
 - () IIA2 Invasive carcinoma >4 cm in greatest dimension
 - IIB With parametrial invasion but not up to the pelvic wall
- \bigcirc III The carcinoma involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or non-functioning kidney and/or involves pelvic and/or paraaortic lymph nodes°
 - IIIA Carcinoma involves lower third of the vagina, with no extension to the pelvic wall
 - IIIB Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney (unless known to be due to another cause)
 - () IIICInvolvement of pelvic and/or paraaortic lymph nodes (including micrometastases),^o irrespective of tumour size and extent (with r and p notations)^p
 - \bigcirc IIIC1 Pelvic lymph node metastasis only
 - \bigcirc IIIC2 Paraaortic lymph node metastasis
- \bigcirc IV The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. A bullous oedema, as such, does not permit a case to be allotted to stage IV
 - IVA Spread of the growth to adjacent organs
 - IVB Spread to distant organs
- Reprinted from Int J Gynaecol Obstet., Volume 143 Suppl 2, Bhatla N, Aoki D, Sharma DN and Sankaranarayanan R, Cancer of the cervix uteri, pages 22-36, 2018, with permission from Wiley (incorporating any FIGO staging published up until 20th October 2021).
- ^mImaging and pathology can be used, when available, to supplement clinical findings with respect to tumour size and extent, in all stages. Pathological findings supercede imaging and clinical findings.
- ⁿ The involvement of vascular/lymphatic spaces does not change the staging. The lateral extent of the lesion is no longer considered.
- ° Isolated tumour cells do not change the stage but their presence should be recorded.
- ^p Adding notation of *r* (imaging) and *p* (pathology), to indicate the findings that are used to allocate the case to stage IIIC. For example, if imaging indicates pelvic lymph node metastasis, the stage allocation would be Stage IIIC1r and, if confirmed by pathological findings, it would be Stage IIIC1p. The type of imaging modality or pathology technique used should always be documented. When in doubt, the lower staging should be assigned.

TNM Staging (UICC Cervix Uteri TNM 2021)⁹

- TNM Descriptors (only if applicable) (select all that apply) m - multiple primary tumours l r - recurrent y y post-therapy Primary tumour (pT)) TX Primary tumour cannot be assessed Т0 No evidence of primary tumour Tis Carcinoma in situ (preinvasive carcinoma) T1 Tumour confined to the cervix (extension to the corpus should be disregarded)^r T1a Invasive carcinoma diagnosed only by microscopy; stromal invasion with a maximum depth of 5.0 mm^s T1a1 Measured depth of stromal invasion 3.0 mm or less in depth T1a2 Measured depth of stromal invasion more than 3.0 mm and not more than 5.0 mm^t ○ T1b Lesion confined to the cervix with depth of invasion greater than 5 mm) T1b1 Lesion 2.0 cm or less in greatest dimension T1b2 Lesion more than 2.0 cm in greatest dimension but no more than 4.0 cm in greatest dimension T1b3 Lesion more than 4.0 cm in greatest diameter () T2 Tumour invades beyond uterus but not to pelvic wall or to the lower third of vagina () T2a Tumour without parametrial invasion T2a1 Lesion 4.0 cm or less in greatest dimension T2a2 Lesion more than 4.0 cm in greatest dimension T2b Tumour with parametrial invasion) T3 Tumour involves lower third of vagina, or extends to pelvic wall, or causes hydronephrosis or nonfunctioning kidney 🔿 T3a Tumour involves lower third of vagina Tumour extends to pelvic wall, or causes T3b hydronephrosis or nonfunctional kidney) T4 Tumour invades mucosa of bladder or rectum, or extends beyond true pelvis^u Regional lymph nodes (pN)) NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis Ν1 Regional lymph node metastasis to pelvic lymph nodes only^{v,w} () N2 Regional lymph node metastasis to paraaortic lymph nodes, with or without positive pelvic lymph nodes^{v,w} Distant metstasis (pM)) Not applicable Μ1 Distant metastasis (includes inguinal lymph nodes
 - and intraperitoneal disease). It excludes metastasis to vagina and pelvic side wall, but does include uterine serosa, and adnexa^x

^q Reproduced with permission. Source: UICC TNM Classification for Carcinoma of the cervix, Cervix Uteri TNM 2021, eds by James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. 2021, Publisher Wiley (incorporating any errata published up until 25th January 2022).

- Extension to the corpus uteri should be disregarded.
- ^s Vascular space involvement, venous or lymphatic, does not affect classification.
- The depth of invasion should be taken from the base of the epithelium, either surface or glandular, from which it originates. The depth of invasion is defined as the measurement of the tumour from the epithelial-stromal junction of the adjacent most superficial papillae to the deepest point of invasion.
- ^u Bullous oedema is not sufficient to classify a tumour as T4.
- ^v The suffix (mi) is added if the lymph node metastases is >0.2 mm but ≤2 *mm*.
- $^{\rm w}$ The suffix (sn) is added if the metastases is identified by sentinel node biopsy.
- ^x FIGO excludes uterine serosa and adnexal involvement from M1. UICC aligns with AJCC which also includes uterine serosa and adnexal involvement in M1.

Use of this dataset is only permitted subject to the details described at: Disclaimer - International Collaboration on Cancer Reporting (iccr-cancer.org) Version 5.0 Published October 2023 ISBN: 978-1-922324-43-6 Page 5 of 5